We are live on ! Find out more
PC

Polar Capital Portfolio holdings

AUM $13.5B
1-Year Est. Return 55.9%
This Fund
S&P 500
This Quarter Est. Return
+4.91%
1 Year Est. Return
+55.9%
3 Year Est. Return
+127.44%
5 Year Est. Return
+269.08%
10 Year Est. Return
–
AUM
$5.3B
AUM Growth
-$16.8M
Cap. Flow
-$266M
Cap. Flow %
-5.01%
Top 10 Hldgs %
22.18%
Holding
297
New
35
Increased
74
Reduced
86
Closed
35

Top Buys

Rank Stock Value
1
PFE icon
Pfizer
PFE
+$60.5M
2
SPGI icon
S&P Global
SPGI
+$52.3M
3
BMY icon
Bristol-Myers Squibb
BMY
+$41.3M
4
AGN
Allergan plc
AGN
+$38.2M
5
LVNTA
Liberty Interactive Corporation Series A Liberty Ventures
LVNTA
+$37.2M

Top Sells

Rank Stock Value
1
JNJ icon
Johnson & Johnson
JNJ
+$98.3M
2
LLY icon
Eli Lilly
LLY
+$54.1M
3
AAPL icon
Apple
AAPL
+$51.2M
4
FIS icon
Fidelity National Information Services
FIS
+$42.9M
5
SYK icon
Stryker
SYK
+$40.2M

Sector Composition

Rank Sector Weight
1 Healthcare 25.18%
2 Financials 21.66%
3 Technology 21.39%
4 Communication Services 9.45%
5 Consumer Discretionary 5.7%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ACAD icon
226
Acadia Pharmaceuticals
ACAD
$4.25B
$987K 0.02%
+30,393
New +$1.02M
VIVO
227
DELISTED
Meridian Bioscience Inc
VIVO
$834K 0.02%
42,800
– –
PRTK
228
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
$824K 0.02%
+59,230
New +$872K
AA icon
229
Alcoa
AA
$11.7B
$812K 0.02%
36,457
-4,517
-11% -$106K
CASH icon
230
Pathward Financial
CASH
$1.81B
$600K 0.01%
35,319
-16,827
-32% -$275K
APIC
231
DELISTED
Apigee Corporation Common Stock
APIC
$577K 0.01%
47,278
-193,615
-80% -$2.06M
RCKT icon
232
Rocket Pharmaceuticals
RCKT
$348M
$504K 0.01%
+16,926
New +$595K
CFG icon
233
Citizens Financial Group
CFG
$30.4B
$495K 0.01%
24,794
-2,527
-9% -$56.1K
LAB icon
234
Standard BioTools
LAB
$326M
$489K 0.01%
54,132
-10,360
-16% -$97.4K
BKD icon
235
Brookdale Senior Living
BKD
$3.62B
$417K 0.01%
27,019
– –
ADAP
236
DELISTED
Adaptimmune Therapeutics
ADAP
$408K 0.01%
50,000
– –
NVTA
237
DELISTED
Invitae Corporation
NVTA
$406K 0.01%
+55,000
New +$513K
AKAO
238
DELISTED
Achaogen Inc
AKAO
$379K 0.01%
+100,000
New +$348K
OCUL icon
239
Ocular Therapeutix
OCUL
$1.86B
$371K 0.01%
74,873
+44,873
+150% +$445K
ALKS icon
240
Alkermes
ALKS
$8.82B
$339K 0.01%
7,852
-8,916
-53% -$368K
OPB
241
DELISTED
Opus Bank Common Stock
OPB
$331K 0.01%
+9,803
New +$347K
HSTO
242
DELISTED
Histogen Inc. Common Stock
HSTO
$322K 0.01%
783
– –
RARE icon
243
Ultragenyx Pharmaceutical
RARE
$2.65B
$240K ﹤0.01%
4,917
-8,315
-63% -$538K
A icon
244
Agilent Technologies
A
$39.1B
– –
-600,000
Closed -$23.9M
AEM icon
245
Agnico Eagle Mines
AEM
$72.6B
– –
-60,000
Closed -$2.21M
ALLT icon
246
Allot
ALLT
$374M
– –
-122,039
Closed -$635K
BFH icon
247
Bread Financial
BFH
$4.21B
– –
-17,285
Closed -$3.03M
CVS icon
248
CVS Health
CVS
$137B
– –
-302,347
Closed -$31.4M
LXRX icon
249
Lexicon Pharmaceuticals
LXRX
$1.02B
– –
-30,000
Closed -$359K
PRLB icon
250
Protolabs
PRLB
$1.86B
– –
-175,697
Closed -$13.5M
8 9
10
11 12

Similar funds

ECM
ETrade Capital Management Arlington, Virginia $5.37B AUM 10.84% 1-Year Est. Return
FAAS
First Allied Advisory Services San Diego, California $2.98B AUM 15.89% 1-Year Est. Return
WAM
Wealthspire Advisors (Maryland) Potomac, Maryland $2.84B AUM 10.91% 1-Year Est. Return
FS
Feinberg Stephen $2.61B AUM 15.12% 1-Year Est. Return
NIMC
NWQ Investment Management Company Los Angeles, California $2.22B AUM 6.84% 1-Year Est. Return
TI
TT International London, United Kingdom $1.94B AUM
VIM
Veritas Investment Management London, United Kingdom $1.65B AUM 25.54% 1-Year Est. Return
PS
Peter Svennilson $1.23B AUM 301.34% 1-Year Est. Return

Polar Capital's Q2 2016 Portfolio in Review

As of Q2 2016, Polar Capital held 297 positions worth $5.3B, down 0.32% from $5.32B the previous quarter. Its ten largest holdings account for 22% of the portfolio.

Polar Capital withdrew a net $266M in Q2 2016, closing 35 positions and reducing 86 holdings. Its most notable exit was Stryker, an estimated $40.2M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 25% of assets, up from 23% a quarter earlier, followed by Financials and Technology.

Against the trend, Polar Capital opened a new position in S&P Global worth $52.2M.

  • Polar Capital's largest Q2 2016 buy was S&P Global: 487,049 shares worth $52.2M.
  • Polar Capital added most to Pfizer in Q2 2016, an estimated $60.5M increase.
  • Polar Capital's biggest Q2 2016 reduction was Johnson & Johnson, cutting an estimated $98.3M.
  • Polar Capital fully exited Stryker in Q2 2016, selling an estimated $40.2M.
  • Polar Capital's ten largest holdings make up 22% of its $5.3B portfolio in Q2 2016.
  • Polar Capital opened 35 new positions and closed 35 in Q2 2016.
  • Polar Capital's portfolio value fell 0.32% quarter-over-quarter to $5.3B.

Based on Polar Capital's 13F filing for Q2 2016, filed 15 Aug 2016.